Summary
This chapter describes the role of proteomics in developing personalized management of cancer, which is defined as choice of the best treatment for an individual. Numerous proteomic technologies are available, and selected ones relevant to development of personalized therapy are described. Cancer biomarkers discovered by proteomics can be used for diagnosis as well as drug targets, thus facilitating the integration of diagnostics and therapeutics. Proteomics fulfills many of the requirements for personalized therapy of cancer.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Jain KK. Personalized Medicine: Scientific and Commercial Aspects. Basel, Jain PharmaBiotech Publications, 2007:1–582.
Jain KK. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 2004;5:239–42.
Jain KK. Proteomics: Technologies, Markets and Companies. Basel, Jain PharmaBiotech Publications, 2007:1–564.
Nettikadan S, Radke K, Johnson J, et al. Detection and quantification of protein biomarkers from fewer than ten cells. Mol Cell Proteomics 2006;5:895–901.
Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3:267–275.
Wiesner A. Detection of tumor markers with ProteinChip® technology. Curr Pharm Biotechnol 2004;5:45–67.
Miyata T, Jige M, Nakaminami T, Uragami T. Tumor marker-responsive behavior of gels prepared by biomolecular imprinting. Proc Natl Acad Sci USA 2006;103:1190–3.
Samoylova TI, Morrison NE, Globa LP, Cox NR. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anticancer Agents Med Chem 2006;6:9–17.
Suber RL, Flanders VL, Campa MJ, Patz EF Jr. Accentuation of differentially expressed proteins using phage technology. Anal Biochem 2004;333:351–7.
Da Cruz S, Parone PA, Martinou JC. Building the mitochondrial proteome. Expert Rev Proteomics 2005;2:541–51.
Fong S, Debs RJ, Desprez P-Y, et al. Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 2004;10:387–392.
Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 2004;165:1057–68.
Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005;2:337–48.
Jain KK. Nanobiotechnology: Applications, Markets and Companies. Basel, Jain PharmaBiotech Publications, 2007:1–674.
Venne K, Bonneil E, Eng K, Thibault P. Enhanced sensitivity in proteomics analyses using nanoLC–MS and high-field asymmetry waveform ion mobility mass spectrometry. Anal Chem 2005;77:2176–86.
Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005;102:8315–20.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.
Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 2005;17:118–22.
Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer ? molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133–44.
Yuen HF, Chua CW, Chan YP, et al. Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 2006;19:931–41.
Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393–406.
Iwadate Y, Sakaida T, Saegusa T, et al. Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 2005;26:993–8.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc.
About this chapter
Cite this chapter
Jain, K. (2008). Oncoproteomics for Personalized Management of Cancer. In: Daoud, S.S. (eds) Cancer Proteomics. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-169-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-59745-169-7_4
Publisher Name: Humana Press
Print ISBN: 978-1-58829-858-4
Online ISBN: 978-1-59745-169-7
eBook Packages: MedicineMedicine (R0)